Institute of Human Genetics, Helmholtz Zentrum München, Neuherberg, Germany.
J Med Genet. 2012 Apr;49(4):277-83. doi: 10.1136/jmedgenet-2012-100846.
Next generation sequencing has become the core technology for gene discovery in rare inherited disorders. However, the interpretation of the numerous sequence variants identified remains challenging. We assessed the application of exome sequencing for diagnostics in complex I deficiency, a disease with vast genetic heterogeneity.
Ten unrelated individuals with complex I deficiency were selected for exome sequencing and sequential bioinformatic filtering. Cellular rescue experiments were performed to verify pathogenicity of novel disease alleles.
The first filter criterion was 'Presence of known pathogenic complex I deficiency variants'. This revealed homozygous mutations in NDUFS3 and ACAD9 in two individuals. A second criterion was 'Presence of two novel potentially pathogenic variants in a structural gene of complex I', which discovered rare variants in NDUFS8 in two unrelated individuals and in NDUFB3 in a third. Expression of wild-type cDNA in mutant cell lines rescued complex I activity and assembly, thus providing a functional validation of their pathogenicity. Using the third criterion 'Presence of two potentially pathogenic variants in a gene encoding a mitochondrial protein', loss-of-function mutations in MTFMT were discovered in two patients. In three patients the molecular genetic correlate remained unclear and follow-up analysis is ongoing.
Appropriate in silico filtering of exome sequencing data, coupled with functional validation of new disease alleles, is effective in rapidly identifying disease-causative variants in known and new complex I associated disease genes.
下一代测序已成为发现罕见遗传性疾病基因的核心技术。然而,识别出的大量序列变异的解释仍然具有挑战性。我们评估了外显子组测序在复杂 I 缺陷症(一种遗传异质性很大的疾病)诊断中的应用。
选择了 10 名复杂 I 缺陷症的无关个体进行外显子组测序和连续的生物信息学筛选。进行细胞拯救实验以验证新疾病等位基因的致病性。
第一个筛选标准是“存在已知的致病性复杂 I 缺陷变异”。这揭示了 2 名个体中 NDUFS3 和 ACAD9 的纯合突变。第二个标准是“在复杂 I 的结构基因中存在两个新的潜在致病性变异”,在 2 名无关个体中发现了 NDUFS8 的罕见变异,在第 3 名个体中发现了 NDUFB3 的罕见变异。在突变细胞系中表达野生型 cDNA 可挽救复杂 I 的活性和组装,从而为其致病性提供了功能验证。使用第三个标准“在编码线粒体蛋白的基因中存在两个潜在致病性变异”,在 2 名患者中发现了 MTFMT 的失功能突变。在 3 名患者中,分子遗传学相关性仍不清楚,正在进行随访分析。
对外显子组测序数据进行适当的计算机筛选,结合新疾病等位基因的功能验证,可有效快速识别已知和新的复杂 I 相关疾病基因中的致病变异。